<DOC>
	<DOCNO>NCT00020917</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody cetuximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining monoclonal antibody therapy combination chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine cetuximab combination chemotherapy treat patient stage IV colorectal cancer .</brief_summary>
	<brief_title>Cetuximab Plus Combination Chemotherapy Treating Patients With Stage IV Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety profile cetuximab , irinotecan , leucovorin calcium , fluorouracil patient stage IV colorectal cancer . II . Determine response rate time progression patient treat regimen . OUTLINE : This multicenter study . Patients receive cetuximab IV 1-2 hour weekly week 1-6 . Patients also receive irinotecan IV 90 minute , leucovorin calcium IV 10-15 minute , fluorouracil IV 3-5 minute weekly week 1-4 . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Patients follow 1 month every 3 month thereafter . PROJECTED ACCRUAL : A total 20 patient accrue study within 2 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV colorectal cancer Any T , N , M1 Immunohistochemical evidence epidermal growth factor receptor expression ( least 1+ ) Bidimensionally measurable metastatic disease Meningeal CNS involvement tumor allow PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Granulocyte count least 1,500/mm3 Platelet count least 150,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin normal AST great 5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No history uncontrolled angina , arrhythmia , congestive heart failure Neurologic : No uncontrolled seizure disorder No active neurological disease No grade 2 great neuropathy Other : No malignancy within past 3 year except basal cell skin cancer preinvasive carcinoma cervix No medical psychiatric condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior murine monoclonal antibody therapy No prior cetuximab Chemotherapy : No prior chemotherapy metastatic disease Prior adjuvant chemotherapy stage I , II , III colorectal cancer allow diseasefree 1 year completion therapy first evidence metastatic disease No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy metastatic disease No concurrent radiotherapy Surgery : At least 3 week since prior surgery ( exclude prior diagnostic biopsy ) Other : No prior treatment metastatic colorectal cancer At least 30 day since prior investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>